Purpose The purpose of this study was to evaluate the best protocol to prepare endometrium for frozen embryo replacement (FER) cycles. Methods This study is a systematic review and meta-analysis. Following PubMed and OvidSP search, a total of 1166 studies published after 1990 were identified following removal of duplicates. Following exclusion of studies not matching our inclusion criteria, a total of 33 studies were analyzed. Primary outcome measure was live birth. The following protocols, including true natural cycle (tNC), modified natural cycle (mNC), artificial cycle (AC) with or without suppression, and mild ovarian stimulation (OS) with gonadotropin (Gn) or aromatase inhibitor (AI), were compared. Results No statistically significant difference for both clinical pregnancy and live birth was noted between tNC and mNC groups. When tNC and AC without suppression groups are compared, there was a statistically significant difference in clinical pregnancy rate in favor of tNC, whereas it failed to reach statistical significance for live birth. When tNC and AC with suppression groups are compared, there was a statistically significant difference in live birth rate favoring the latter. Similar pregnancy outcome was noted among mNC versus AC with or without suppression groups. Similarly, no difference in clinical pregnancy and live birth was noted when ACs with or without suppression groups are compared. Conclusions There is no consistent superiority of any endometrial preparation for FER. However, mNC has several advantages (being patient-friendly; yielding at least equivalent or better pregnancy rates when compared with tNC and AC with or without suppression; may not require LPS). Mild OS with Gn or AI may be promising.
Introduction
There has been a recent significant increase in the frozen embryo replacement (FER) cycles not only due to the availability of surplus embryos but also due to cryo-all cycles to avoid the risk of ovarian hyperstimulation syndrome [1] , preimplantation genetic screening [2] , and concerns for detrimental effect of controlled ovarian stimulation on endometrial receptivity in a fresh cycle [3] . The 2011 results, published in 2016, generated from European registers by ESHRE reported that the proportion of FER cycles was 32.3 % [4] compared to 28 % in 2010 [5] . As concordant with the European data, the proportion of FER cycles was 24.5 % as reported by the most recent US nationwide database [6] . Improved laboratory techniques and especially enhanced survival and implantation rates achieved by vitrification have also contributed to the increasing trend for performing FER cycles.
Despite the increased interest in FER and personalized approaches in reproductive medicine, the best-individualized approach to prepare endometrium for FER is still a matter of debate [7, 8] . Furthermore, although the data are lacking, one may need to take the etiology of infertility (e.g., endometriosis) into account while assigning the FER protocol. The available protocols to be used for FER include (i) true natural cycle (tNC), (ii) modified natural cycle (mNC), (iii) artificial cycle (AC) without suppression, (iv) AC with suppression, and (v) mild ovarian stimulation (OS) with gonadotropins (Gns) or aromatase inhibitor (AI).
True natural cycle can only be employed in regularly cycling women. In a tNC, ultrasonographic and endocrine monitoring is performed to delineate the timing of spontaneous ovulation. Endocrine monitoring should be performed in such cycles to verify the timing of luteinizing hormone (LH) surge. When a rise in serum LH levels is noted, it is assumed that ovulation will occur in 36-40 h later [9] . Urinary LH kits might be patient-friendly but might be misleading [10] . Therefore, it is better to monitor circulating LH levels daily during the time of ovulation. There is paucity of data on the need for luteal phase support (LPS) in tNC [11] .
Frequent endocrine and ultrasonographic monitoring may be cumbersome in tNC. Hence, mNC may be more patientfriendly. In mNC, following a baseline scan on day 2/3 of menses, ultrasonographic monitoring is generally started on day 8-10 and continued on alternate days or daily until the dominant follicle reached 16-20 mm in diameter during which human chorionic gonadotropin (hCG) triggering is employed. Since hCG has a long half-life and has a sustained luteotropic effect in the early luteal phase up to 7 days following administration [12] , LPS might not be needed in mNC [13, 14] .
Artificial cycles may be performed in all women regardless of the menstrual regularity and offer the greatest flexibility for timing of FER. Although AC with suppression is robust to avoid ovulation, AC without suppression is more patient-friendly. However, premature ovulation leading to cycle cancellation, encountered in 1.9 to 7.4 % of the cycles, is the main drawback of AC without suppression [15, 16] . Luteal phase should be supported in AC with or without suppression.
Another option to prepare endometrium in FER is to employ mild stimulation with either exogenous gonadotropins or oral agents. In regularly cycling women, it has been hypothesized that ovarian stimulation with either oral agents or exogenous gonadotropins (Gns) may improve certain defects in the follicular and subsequent luteal phase, resulting in a better endometrial preparation for embryo implantation [17, 18] . However, it has also been claimed that ovarian stimulation may lead to decreased endometrial receptivity [3, 19, 20] .
There is a paucity of well-designed randomized controlled trials (RCTs) and systematic reviews [8, 21] to evaluate the best protocol(s) to prepare endometrium for FER. In this systematic review and meta-analysis, we overviewed the available evidence in this context.
Material and methods
In this systematic review, we strictly incorporated the guidelines by the PRISMA statement.
Definition of protocols
True natural cycle was defined when frozen embryo transfer had been performed after documentation of spontaneous ovulation with ultrasonographic and/or endocrine monitoring. Studies employing endocrine monitoring with either serum or urinary LH levels were included. Modified natural cycle was defined when the leading follicle (16-20 mm) was triggered with hCG. Regarding tNC and mNC, studies that did or did not employ LPS were included.
In AC cycles, oral estrogen was commenced on the first, second, or third day of the cycle with the aim of supporting endometrial proliferation and suppressing follicle growth. Estrogen was used either at a fixed dose (6 mg daily) or in an incremental fashion (2 to 6 mg daily). After 12-14 days of estrogen use, vaginal ultrasound examination was performed to confirm that no dominant follicle had emerged and to measure endometrial thickness. When the endometrial thickness exceeded 7 mm, progesterone supplementation was commenced and FER was scheduled accordingly. This group was further divided according to addition of a gonadotropinreleasing hormone (GnRH) analog as AC with suppression or not as AC without suppression. Mild ovarian stimulation was defined when the follicle cohort was induced either with <150 IU Gn daily or with an AI.
Search strategy and study selection
Criteria for inclusion in the study were established before literature search. Inclusion was limited to studies that were published of RCTs or prospective/retrospective cohort studies, comparing different FER endometrial preparation protocols. A thorough search of PubMed and OvidSP databases was performed using the keywords (endometrial preparation, frozen embryo transfer, cryo-thawed, natural cycle frozen embryo transfer, modified natural cycle embryo transfer, artificial frozen cycle, artificial frozen cycle with gonadotropin suppression) and MeSH terms (cryopreservation and pregnancy).
After screening from the title and abstract, we excluded the data published as abstract, meeting proceeding, book chapter, or review articles and irrelevant studies that did not give any information for the preparation of the endometrium in FER cycles. Case-series, case-control studies, abstracts, and articles published in languages other than English were excluded. Studies before January 1990 and donor-recipient cycles were excluded. The primary end-point was taken as live birth rate, and the secondary outcome measure was taken as clinical pregnancy rate.
An extensive literature search was performed up to April 2016 in PubMed and OvidSP by two blind investigators (S.M. and M.P.) to generate the meta-analyses. The search strategy yielded a total of 4144 and 1332 references, from PubMed and OvidSP, respectively (Fig. 1) . After removal of duplicates (n = 1166), all remaining studies were examined in detail from the title and abstract. We excluded the data published as abstract, meeting proceeding, book chapter, or review articles and irrelevant full-article studies that did not give any information on FER cycles (n = 1126). Of the remaining 40 studies, 9 were excluded due to being abstract only [22] [23] [24] [25] [26] [27] [28] [29] [30] . Literature search was also performed on references from identified studies, and two new studies [31, 32] were retrieved, making a total of 33 studies (Fig. 1) .
The meta-analysis was performed employing RevMan 5.3 software (The Nordic Cochrane Centre, The Cochrane Collaboration). The I 2 statistics was used to assess the statistical heterogeneity, and >50 % was considered to assign heterogeneity. A random-effect model was used in case of statistical heterogeneity whereas a fixed-effect model was used in the absence of heterogeneity. To weigh the scores of individual studies, the inverse-variance method was employed. Odds ratios (ORs) were used to pool available data regardless of the design of the included studies. The Mantel-Haenszel method was applied to estimate the pooled effect size. A priori specified subgroup analyses were performed. A two-sided significance level of p < 0.05 was used.
Results

Studies included for meta-analyses
A total of 40 studies were left after screening from title, abstract, or manuscript, and 33 were finally included for quantitative final analysis (Fig. 1) . Of the 33 studies included in this meta-analysis, only 11 were RCTs. The remaining 22 studies were retrospective cohort studies with their inherent selection bias. The detailed description of the included studies is given in Table 1 .
tNC versus mNC
A total of five studies, two RCTs [33, 34] and three retrospective cohort studies [35] [36] [37] , making a total of 2081 embryo transfer (ET) cycles, were included.
The pooled estimates for clinical pregnancy (OR 0.90, 95 % CI 0.73-1.12; five studies) and live birth (OR 0.82, 95 % CI 0.63-1.08; three studies) are given in Fig. 2 . No statistically significant difference for both clinical pregnancy and live birth was noted between tNC and mNC groups.
In two studies, no LPS was employed in both tNC and mNC arms [33, 37] . However, LPS was administered to both tNC and mNC arms in another two studies [34, 35] . In the study by Tomas et al. [36] , no LPS was given to the mNC group whereas LPS in the form of vaginal progesterone gel or micronized progesterone tablet was administered to the tNC group. Among available studies that employed or did not employ LPS, comparable clinical pregnancy rates were noted between the tNC and mNC groups (Fig. 2) . With LPS, the OR for clinical pregnancy was 0.92 (95 % CI 0.63-1.36; two studies); the OR for the only available study reporting live birth was 0.45 (95 % CI 0.13-1.65; one study). Without LPS, the OR for clinical pregnancy was 1.34 (95 % CI 0.56-3.23; two studies); with the only available study reporting live birth, the OR was 0.82 (95 % CI 0.37-1.83; one study).
tNC versus AC without suppression
A total of eight studies, all being retrospective cohort studies [35, 36, [38] [39] [40] [41] [42] [43] , making a total of 8762 ET cycles, were included.
The pooled estimates for clinical pregnancy and live birth are given in Fig. 3 . There was a statistically significant difference in clinical pregnancy rate in favor of tNC (OR 1.46, 95 % CI 1.07-1.99; seven studies), whereas it failed to reach statistical significance for live birth (OR 1.80, 95 % CI 0.92-3.49; three studies).
In the most recent study by Orvieto et al. [41] , different LPS strategies have been employed during two time periods; in the tNC arm, during 2012-2014, micronized progesterone soft gel vaginal capsule at a dose of 3 × 200 mg or vaginal bioadhesive gel at 90 mg (8 %) was employed whereas during 2014-2015, in addition to vaginal progesterone, luteal rhCG 250 mcg and 0.1 mg triptorelin were administered. Hence, the time periods employing different LPS strategies have been (Fig. 3) .
In two studies, no LPS was administered in the tNC arm [35, 38] ; there was a statistically significant difference in clinical pregnancy rate favoring tNC against AC without suppression (OR 1.63, 95 % CI 1.24-2.14; two studies). Luteal phase support was given in five studies [36, [40] [41] [42] [43] ; the ORs for clinical pregnancy and live birth rates were not significantly different (OR 1.32 (95 % CI 0.90-1.93; four studies) and 1.47 (95 % CI 0.72-3.03; two studies), respectively).
tNC versus AC with suppression
A total of six studies, one RCT [44] and one quasi-randomized [45] and four retrospective cohort studies [46] [47] [48] [49] , making a total of 2933 ET cycles, were included.
The pooled estimates for clinical pregnancy and live birth are given in Fig. 4 . There was a significant difference favoring AC with suppression for live birth (OR 0.73, 95 % CI 0.56-0.95; four studies), whereas it failed to reach statistical significance for clinical pregnancy (OR 0.83, 95 % CI 0.69-1.00; six studies). The study by Hill et al. [48] , being a retrospective cohort study, with a total of 1391 ET cycles, dominated the analyses for both the clinical pregnancy and live birth rates.
In three studies, LPS was not employed in the tNC arm [44, 46, 47] . In only one study, LPS was administered in the tNC arm [48] . Without LPS, there was no significant difference for clinical pregnancy (OR 1.09, 95 % CI 0.73-1.63; three studies) or live birth rates (OR 0.96 95 % CI 0.64-1.46; three studies). With LPS, based on a single study, the ORs for clinical pregnancy and live birth were 0.65 (95 % CI 0.48-0.87; one study) and 0.62 (95 % CI 0.44-0.87; one study), respectively, favoring AC with suppression (Fig. 4) . A total of six studies, one RCT [50] and five retrospective cohort studies [32, 35, 36, 51, 52 ] making a total of 6074 ET cycles, were included.
The pooled estimates for clinical pregnancy and live birth are given in Fig. 5 . There was no statistically significant difference between these two protocols regarding clinical pregnancy (OR 1.11, 95 % CI 0.88-1.41; six studies) and live birth rates (OR 1.14, 95 % CI 0.96-1.37; four studies).
In two studies, no LPS was employed in the mNC arm [36, 50] . Without LPS, there was no significant difference for clinical pregnancy (OR 1.08, 95 % CI 0.88-1.33; two studies) or live birth rates (OR 1.23 95 % CI 0.98-1.55; two studies). In four studies, LPS was administered in the mNC arm [32, 35, 51, 52] With LPS, the ORs for clinical pregnancy and live 
mNC versus AC with suppression
A total of two retrospective cohort studies [53, 54] with a total of 1174 ET cycles were included. LPS has been administered in the mNC arm in both studies.
The pooled estimates for clinical pregnancy (OR 1.50, 95 % CI 1.12-2.00; two studies) and live birth (OR 1.24, 95 % CI 0.76-2.03; one study) are given in Fig. 6 .
AC with suppression versus AC without suppression
A total of five studies, four RCTs [15, [55] [56] [57] and one retrospective cohort study [16] , making a total of 1752 ET cycles, were included. 
Natural cycle (either tNC or mNC) versus mild OS with Gn
A total of five studies, one RCT [18] and four retrospective cohort studies [45, 53, 58, 59] , making a total of 1451 ET cycles, were included. In two studies tNC [45, 58] was employed, and in three studies mNC [18, 53, 59 ] was employed.
The pooled estimates for clinical pregnancy (OR 1.10, 95 % CI 0.85-1.41; five studies) and live birth (OR 0.73, 95 % CI 0.46-1.17; two studies) are given in Fig. 8 . When subgroup analysis was performed comparing tNC versus OS with Gn, and mNC versus OS with Gn, the pooled estimates for clinical pregnancy were OR 1.20, 95 % CI 0.65-2.20 (two studies), and OR 0.84, 95 % CI 0.39-1.78 (three studies), respectively.
AC (with or without suppression) versus mild OS with Gn or AI (letrozole)
A total of four studies, two RCTs [60, 61] and two retrospective cohort studies [53, 58] , making a total of 1850 ET cycles, were included.
The pooled estimates for clinical pregnancy (OR 0.82 95 % CI 0.68-0.99; four studies) and live birth (OR 0.71, 95 % CI 0.56-0.90; three studies) are given in Fig. 9 . There appears to be increased clinical pregnancy and live birth rates employing OS with Gn or AI (letrozole).
Discussion
In the current meta-analysis, we failed to observe consistent superiority of a particular protocol to prepare endometrium for FER cycles when different available protocols were compared, in concordant with previous two meta-analyses [8, 21] . The best evidence was available for the comparison of AC with or without suppression (four RCTs), and no difference in clinical pregnancy and live birth rates were noted. However, although statistical significance was noted at several two-sided comparisons of the available protocols, none of them was noted to be consistently superior. Of note, mNC appeared to yield at least equivalent or better pregnancy rates when compared with tNC and AC with or without suppression. Of the available RCTs, the ANTARCTICA trial had the largest sample size and concluded that mNC and AC without suppression had similar live birth rates. Endometrial preparation with ovarian stimulation with either Gn or AI (letrozole) may be promising and warrants further powerful RCTs.
In the current meta-analysis, vast majority of the data is achieved from retrospective studies. Obviously, combining retrospective cohort studies with RCTs in the same metaanalysis may introduce selection bias. On the other hand, it is of interest that despite an increasing trend in the performance of FER cycles in the last decade, there is still a paucity of well-designed, powerful RCTs to delineate the best protocol to prepare endometrium.
Although the lack of use of any medication is an advantage of tNC, the need of frequent endocrine and ultrasonographic monitoring is a drawback. Obviously, mNC is performed with less such monitoring. In this meta-analysis, tNC and mNC appear to be associated with similar clinical pregnancy and live birth rates. In this comparison, there are two RCTs [33, 34] , with opposing results. Fatemi et al. [33] concluded that tNC is superior to mNC whereas Weissman et al. [34] reported a similar pregnancy outcome. The differences in study protocols might have contributed to contradictory results. In the study by Weisman et al. [34] , if an LH surge was noted, hCG was not administered and the cycle was cancelled. An LH surge at the time of hCG administration was not a cancellation criterion in the study by Fatemi et al. [33] ; it is of note that, in this study, among 23 patients with impending spontaneous LH surge and hCG administration, only 1 (4.3 %) conceived [33] . However, the detrimental effect of spontaneous LH surge at the time of hCG administration is controversial [62, 63] . Another contributory factor for discordant results might be the administration of LPS or not; LPS had been administered in the study by Weismann et al. [34] , whereas no LPS was given in the study by Fatemi et al. [33] .
The need for LPS in tNC is controversial; there is only one RCT evaluating the impact of LPS with vaginal progesterone administration on live birth rates in tNC cycles [11] . In this study by Bjuresten et al., 435 women undergoing tNC were randomized to either vaginal progesterone (400 mg vaginal micronized progesterone bid) or no LPS [11] . The primary outcome measure was live birth rate. Administration of LPS was associated with statistically significant increase in live birth rate (30 versus 20 %; p = 0.027). Luteal phase support may not be required in mNC cycles due to sustained luteotropic effect of hCG used [12] . In the current study, when subgroup analysis was performed with administration of LPS or not, no significant difference with regard to clinical pregnancy and live birth was noted among the tNC and mNC arms.
When tNC and AC without suppression are compared, there appears to be a statistical significance for clinical pregnancy favoring tNC. Of the included seven studies, there was no RCT. Inferior pregnancy outcome in AC cycles without suppression might be due to escape from pituitary suppression, which is encountered in 1.9 to 7.4 % of such cycles [15, 16] Of the seven included studies, both endocrine and ultrasonographic monitoring was performed in only two studies in the AC without suppression arm, which might have contributed to inferior pregnancy outcome in our meta-analysis [38, 41] . Finally, lack of homogenous assignment of either anovulatory or ovulatory patients to both arms, with their different propensity for escape from ovulation, may introduce allocation bias. In two out of seven studies included in this analysis, only anovulatory patients had been enrolled in the AC without suppression arm, whereas ovulatory women had been enrolled in the tNC arm [38, 43] .
When tNC and AC with suppression are compared, the latter is associated with significantly higher live birth rate and marginally significant difference regarding clinical pregnancy rate. Of the six studies included, there is one RCT [44] and one quasi-randomized trial [45] with both studies reporting no difference.
There appears to be no significant difference in clinical pregnancy and live birth rates among the mNC and AC without suppression groups. Of the six studies included, there is one powerful, multi-center RCT (ANTARCTICA trial) reporting comparable live birth rates [50] . However, significantly more cycles had been cancelled in the AC without suppression group (124/464 versus 101/495, OR 1.4, 95 % CI 1.1-1.9, p = 0.02). Apart from inadequate embryo survival, the main reasons for cycle cancellation in the mNC and AC without suppression groups were ovulation prior to hCG injection (21/101, 20.8 %) and insufficient endometrial thickness (37/124, 29.8 %), respectively. The costs of two endometrial preparation methods were comparable.
There are only two retrospective studies comparing mNC and AC with suppression [53, 54] . There appears to be a significant difference favoring mNC regarding clinical pregnancy, which was unexpected. However, since the number of available studies is limited, no definitive conclusion can be made. There appears to be no difference in clinical pregnancy and live birth rates when the AC with and without suppression groups are compared. Of the five studies included, four are RCTs [15, 31, 55, 57] .
If natural cycle, either tNC or mNC, is planned, female age might also be taken into consideration, since unexpected aberrant ovulatory patterns, from anovulation to premature ovulation from 14-16-mm-sized follicles, may be observed in women with advanced female age. In such women, AC with or without suppression might be preferred to avoid such difficulties in timing of FER.
To prepare endometrium for FER, one may consider mild OS with either Gn or AI (letrozole) to overcome subtle defects in folliculogenesis and hence luteal phase in a spontaneous cycle. When NC and OS with Gn groups are compared, there appears to be no difference regarding clinical pregnancy and live birth rates. Of the five studies included, there is one RCT and four retrospective studies. When subgroup analysis is performed splitting NC as tNC and mNC, there is still no difference in clinical pregnancy.
When AC (with or without suppression) is compared with OS with Gn or AI, there appears to be a significant difference in clinical pregnancy and live birth favoring the latter group. Of the four studies included, two are RCTs [60, 61] and the remaining two are retrospective cohort studies [53, 58] . These data suggest that mild stimulation with either Gn or AI may overcome subtle defects in folliculogenesis, potentially correct luteal phase, and hence improve endometrial receptivity. Since high endometrial aromatase P450 mRNA expression is associated with poor IVF outcome [64] , correction of such subtle defects with AI might contribute to better pregnancy rates with such treatment. However, further powerful RCTs are warranted to make definitive conclusions.
To add more clinical heterogeneity to the available studies to prepare endometrium for FER in AC (with or without suppression), different approaches may be employed to prime endometrium with estrogen and to support the luteal phase. Estrogen priming may be done with different routes (oral or transdermal) and dose schemes (incremental or fixed dosing). Most studies have used oral micronized estradiol (E 2 ) 4-6 mg per day. To our knowledge, there is no study comparing oral and transdermal estrogen in non-donor FER cycles. However, in a recent large-scale retrospective case-control study encompassing 8362 fresh ET in donor cycles, no significant difference in live birth rate was found between oral (32.9 %) and transdermal (33.2 %) routes [65] .
The need for endocrine and ultrasonographic monitoring in AC without suppression is controversial. In such cycles, the risk of cycle cancellation due to escape from suppression and hence premature ovulation has been reported to vary from 1.9 to 7.4 % [15, 16] . A delay in estrogen initiation [66] or an insufficient estrogen dose [57] might be associated with a higher risk of such premature ovulation. An additional preventive measure to further reduce the incidence of premature progesterone rise might be the use of higher estrogen starting doses (e.g., 6 mg daily from day 1 to day 3 of the cycle onwards), to further suppress gonadotropin release and prevent the occurrence of follicular dominance and excessive LH secretion [57] . However, in the above-mentioned large-scale retrospective case-control study encompassing 8362 fresh ET in donor cycles, employing AC with suppression, no significant difference in live birth rate was found between incremental or constant estrogen dosing [65] .
With regard to LPS, different approaches might be employed. Although progesterone is the main hormone used for LPS, other approaches such as hCG and GnRH agonist might be employed in the luteal phase [41] . Furthermore, the use of hCG in mNC not only triggers final oocyte maturation but also has luteotrophic effect in the early luteal phase. Although there is substantial evidence that intramuscular and vaginal routes have comparable ongoing pregnancy/live birth rates [67] in fresh autologous cycles, there is controversy in FER cycles. In FER cycles, some studies reported better pregnancy outcome with intramuscular route [68, 69] , whereas the majority of the studies reported similar pregnancy outcome [70] [71] [72] .
The endometrial thickness and pattern were not taken as outcome measures in our meta-analysis. The impact of endometrial thickness and pattern on pregnancy rates in FER cycles is controversial. In a retrospective observational study, an endometrial thickness of 9-14 mm on the day of progesterone supplementation was associated with significantly higher implantation and pregnancy rates compared with an endometrial thickness of 7-8 mm [73] . However, neither endometrial thickness nor endometrial pattern had any impact on implantation and pregnancy rates following euploid blastocyst transfer [74] .
The type of freezing method, slow freezing versus vitrification, might have an impact on post-thaw embryo development and metabolism [75, 76] . A higher post-thaw developmental rate of vitrified embryos might entail the need to change the endometrial preparation protocol, in particular the timing of progesterone commencement in artificial cycles, in order to obtain a better synchrony between embryos and endometrium. However, to our knowledge, there is no available data that compares different progesterone commencement timings and pregnancy outcome based on the type of freezing method employed.
In conclusion, with the best available evidence, there is no consistent superiority of any endometrial preparation for FER. However, mNC has several advantages including the following: (i) being patient-friendly; (ii) yields at least equivalent or better pregnancy rates when compared with tNC and AC with or without suppression; (iii) may not require LPS. Mild OS with Gn or AI may be promising. Further, powerful RCTs are warranted not only to delineate the best protocol to prepare endometrium for FER in selected circumstances but also to evaluate cost-effectiveness and patient convenience.
